67-第67章 多发性肌炎和皮肌炎

可乐加水

随着免疫抑制治疗的出现，特发性炎性肌病的预后不断改善。皮质激素出现前成人特发性炎性肌病的5年生存率为60%,1947一1968年为 68%，近几年为 80 。用通信方式对1986一1998年的59例特发性炎性肌病病人进行了随访，一年生存率为90%,2-5年生存率为80%。前5年共死亡12例，其中死于肺内感染5例，肺纤维化4例，肿瘤3例。发病前3年病情较重，激素用量大，激素减量或停用时病情易复发;发病5年后病情趋于稳定，有三分之一的病人脱离激素，病情仍保持稳定。我们的病人多数较重，病例也较少，因此，这些统计数字与实际情况可能会有差异，它只是在一定程度上也反映了一种趋向。除使用免疫抑制剂外，早诊断早治疗，以及有效控制并发症也有助于预后的改善。
  K* p% ~5 Q# ~# P/ t: c" |. n                                                                                                                (吴东海)
      参考文献：

& `" Q0 ]1 }$ r2 e# a2 }0 P" p" v       马丽，王丽英，侯广庆，等 皮肌炎多发性肌炎59例随访.中华风湿病学杂志，5:59一61   
* o7 u' r" V) o! m4 L# [
7 [5 d' U3 r; m2 O      Askanas V, Engel W N. Sporadic inclusion-body myositisand hereditary inclusion body myopathies: current concepts of di-agnosis and pathogenesis. Curr Opin Rheumatol, 1998.10:530  
& n% m( A  i4 l4 h% {1 D- g$ q
      Ausem M G E M, Lochman P, van Diggelen O P, et al. Adiagnostic test for adult-onset glycogen storage disease type 11.Neurology, 1999.52:851  

1 C$ n. |3 a0 j6 }# ]      Behrens L, Bender A, Johnson M A, et al. Cytotoxic mech-anisms in inflammatory myopathied co-expression of Fas and pro-tective Bcl-2 in muscle fibers and inflammatory cells. Brain,1997. 120:929
5 J: y5 Y2 O* u4 m$ n+ g9 K
      Dalakas M C,Dambrosia J M. A controlled trial of high-doseintravenous immuneglobulin infusions as treatment for dermato-myositis. N Engl J Med, 1993. 329:1993一2000
6 V7 ^2 m7 ~3 b4 Q
* U+ r' ^3 Y' D3 z( \& q      Fafalak R G, Peterson M G, Kagen L J. The strength inpolymyositis and dermatomyositis: best outcome in patients treat-ed early. J Rheumatol, 1994.21:643一648
! {/ C7 K* R/ x7 q3 Y8 M7 L2 i. `
3 v; ~# z; Z9 M" A8 ^      Fyher I-M, Moslemi A-R, Mosavia A, et al. Oligoexpres-sion in muscle infiltrating T cells in inclusion body myositis. JNeuroimmunol 1997.79:185
7 _5 W- f, q+ s  W+ s. s; d5 }
      Garlepp M J, Mastaglia F L. Inclusion body myositis. JNeurol Neurosurg Psychiatry, 1996. 60:251一258
5 A8 L8 `% G6 J      Garton M J, Isenberg D A. Clinical features of lupus myosi-tis versus idiopathic myositis: A review of 30 cases.  Br JRheumatol, 1997.36:1067
, v4 ~; Z* x+ H0 z  H7 l  H
7 G5 J. N; e, j6 M* a      Goebels N, Michaelis D, Engelhardt M, et al. Differentialexpression of perforin in muscle-infiltrating T cells in polymyositisand dermatomyositis. J Clin Invest, 1996.97:2905  

; M4 n2 ~* F" j; Q1 g      Gonzalez-Lopez L, Gamez-Nava JI, Sanchez L, et al. Car-diac manifestations in dermato-polymyositis. Clin Exp Rheumatol1996. 14:373
, C' H. k" z# C2 p0 r5 c
4 x( D! I: {3 [' z& t3 Z7 o% F7 S      Mantegazza R, Bernasconi P, Confalonieri P, et al. Inflam-matory myopathies and systemic disorders: a review of im-munopathogenetic mechanisms and clinical features. J Neurol,1997. 244:277
8 g0 C, R% V; z3 O9 R8 [* {
      Marie 1, Horton P-Y, Hachulla E, et al. Pulmonary in-volvement in polymyositis and in dermatomyositis. J Rheumatol,1998. 25:1336

      Naparstek Y, Plotz P H. The role of autoantibodies in au-toimmune disease. Ann Rev Immunol, 1993.11:79一104   
1 i) O% [1 X! R% q' z+ x
      Pascuzzi R M. Drugs and toxins associated with myopathies.Curr Opin Rheumatol, 1998.10:511   
- I; Q0 G4 k5 b0 h) U& `) w
      Pickering M C, Walport M J. Eosinophilic myopathic syn-dromes. Curr Opin Rheumatol,1998. 10:504

      Plotz P H, Rider L G，Targoff I N, et al. NIH conference.Myositis:  immunologic contributions to understanding cause,pathogenesis and therapy. Ann Intern Med, 1995-122: 715一724
% N% D9 k2 x  ?
      Robert L. Wortmann. Inflammatory Diseases of Muscle andOther Myopathies. Kelley’s Textbook of Rheumatology, 6thEd，W. B. Saunders Company. 2001  

      Sieb J P, Ries F, Traber, et al. Recurrent focal myositis.Muscle Nerve, 1997. 20:1205

5 u: m% d9 F8 L, l5 ^( A4 g0 Y( {      Targoff I N, Miller F W, Medsger T A Jr, et al. Classifica-tion criteria for the idiopathic inflammatory myopathies. CurrOpin Rheumatol, 1997.9:527  

" ?4 x; p6 r! M      Villalba L, Hicks J E, Adams E M, et al. Treatment of re-fractory myositis. Arthritis Rheum 1998. 41:392  

4 _$ ?8 M! p+ [# a+ a  f6 A* e      Whitemore S E, Watson R, Rosenshein N B, et al. Der-matomyositis sine myositis:  Association with malignancy.  JRheumatol, 1996.23:1010

! W2 r% Q! ?* Q: _; Z7 v. g/ g& x      Zieglschmid M E, Pandya A G, Cohen S B, et al. Treat-ment of dermatomyositis with methotrexate. J Am Acad Derma-tol, 1995.32:754一757